Ramoset5 mcg

Ramoset is a selective serotonin (5-HT3) receptor antagonist used for the following indications:

Established / Approved Uses

• Prevention of chemotherapy-induced nausea and vomiting (CINV): Ramoset (injectable form) is used for the prevention of nausea and vomiting associated with moderately to highly emetogenic cancer chemotherapy, typically as part of a combination antiemetic regimen with a corticosteroid (e.g., dexamethasone), with or without an NK1-receptor antagonist.
• Diarrhea-predominant irritable bowel syndrome (IBS-D): Ramoset (oral form) is approved in several markets for improving abdominal pain/discomfort and stool-related symptoms in adults with IBS-D, particularly in male patients, per approved labeling in those markets.

Other Uses

• Prevention of postoperative nausea and vomiting (PONV): used in some markets/settings as part of perioperative antiemetic prophylaxis; considered an adjunct/off-label use where not specifically labeled.

Ramoset is not indicated for chronic, unexplained constipation or for diarrhea due to identifiable structural or infectious causes.

Ramosetron Hydrochloride is available as:

• Oral tablets/orally disintegrating tablets (commonly low-microgram strengths, e.g., 2.5 mcg and 5 mcg, for IBS-D).
• Injection (solution for intravenous use, commonly 0.3 mg/2 mL) for prevention of chemotherapy-induced nausea and vomiting.

Each formulation contains Ramosetron Hydrochloride as the active pharmaceutical ingredient, with standard pharmaceutical excipients appropriate to the dosage form.

Ramoset is a highly selective antagonist of the 5-hydroxytryptamine type 3 (5-HT3) receptor. It belongs to the same pharmacological class as ondansetron, granisetron, and palonosetron (setrons), but is distinguished by a longer duration of action and use in irritable bowel syndrome with diarrhea (IBS-D) in addition to its antiemetic role.

By blocking 5-HT3 receptors both centrally (chemoreceptor trigger zone) and peripherally (vagal afferent nerve terminals in the gastrointestinal tract and enteric neurons), Ramoset reduces nausea, vomiting, and, in IBS-D, abnormal gut motility and visceral hypersensitivity.

Selective 5-HT3 (Serotonin) Receptor Antagonist / Antiemetic; used in Ramoset form for chemotherapy-induced nausea/vomiting and IBS-D.

Ramosetron Hydrochloride selectively and competitively antagonizes the 5-hydroxytryptamine type 3 (5-HT3) receptor, a ligand-gated cation channel.

In chemotherapy-induced nausea and vomiting

Cytotoxic chemotherapy causes release of serotonin from enterochromaffin cells in the small intestine. Serotonin activates 5-HT3 receptors on vagal afferent nerve terminals, triggering the vomiting reflex both peripherally and via the chemoreceptor trigger zone in the area postrema. Ramosetron Hydrochloride blocks this signal at both sites, and has a comparatively long receptor dissociation half-life, contributing to a long duration of antiemetic effect.

In diarrhea-predominant IBS

Ramosetron Hydrochloride blocks 5-HT3 receptors on enteric and sensory afferent neurons in the gut, which slows colonic transit, reduces intestinal secretion and motility, and decreases visceral hypersensitivity, improving stool consistency/frequency and abdominal pain in IBS-D.

Oral Ramoset tablets/orally disintegrating tablets should be taken once daily, at approximately the same time each day, with or without food, and swallowed with water (or allowed to dissolve on the tongue if an orally disintegrating formulation).

Injectable Ramoset is administered as a slow intravenous injection or infusion by a healthcare professional, shortly before chemotherapy is started; it must not be self-administered.

Ramoset has the following clinically significant interactions:

• QT-interval-prolonging drugs: Concomitant use with other drugs that prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, some macrolide/fluoroquinolone antibiotics) may additively increase the risk of QT prolongation and arrhythmia; use with caution and consider ECG monitoring if combined.
• Other serotonergic 5-HT3 antagonists: Concurrent use of other 5-HT3 receptor antagonists is generally unnecessary and does not add benefit; avoid duplicate antiemetic therapy from this class.
• Drugs that reduce gut motility (e.g., opioids, anticholinergics): May compound the constipating effect of Ramoset, increasing the risk of severe constipation or bowel obstruction-related complications.
• CYP3A4/CYP1A2-interacting drugs: Ramoset is partly metabolized via hepatic CYP enzymes; strong enzyme inducers/inhibitors could theoretically alter its clearance, though clinically significant interactions of this type are not well established.

Common and clinically important side effects of Ramoset include:

• Constipation — the most common side effect, particularly with the oral form used for IBS-D; usually mild-to-moderate but can rarely be severe, including fecal impaction or ischemic colitis. Seek urgent medical attention for severe abdominal pain, abdominal distension, or bloody stool (see Precautions and Warnings).
• Headache
• Hard or dry stools, abdominal discomfort/bloating
• Nausea (uncommon, since the drug is itself an antiemetic)
• Elevated liver enzymes (usually transient, mild)
• QT-interval prolongation (uncommon; see interactions and precautions)
• Hypersensitivity reactions (rare)

Pregnancy: Data on the use of Ramoset in human pregnancy are limited. Ramoset should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not well established whether Ramoset passes into human breast milk. Caution is advised, and a decision should be made whether to discontinue breastfeeding or discontinue Ramoset, taking into account the importance of the drug to the mother; consult a physician.

Constipation and bowel-related complications: Ramoset used for IBS-D can cause constipation that is occasionally severe, including rare reports of ischemic colitis or fecal impaction. Patients should be advised to stop Ramoset and seek immediate medical attention if they develop severe abdominal pain, abdominal distension, or bloody stools.

QT-interval prolongation: Ramoset should be used with caution in patients with congenital long QT syndrome, electrolyte abnormalities (hypokalemia, hypomagnesemia), or concomitant use of other QT-prolonging drugs (see Interactions).

Hepatic impairment: Use Ramoset with caution in patients with significant hepatic impairment, as drug clearance may be reduced; dose adjustment or closer monitoring may be needed.

Not for chronic constipation: Ramoset should not be used in patients with a history of chronic constipation or bowel obstruction unless the diagnosis has been carefully re-evaluated by a physician.

There is limited clinical experience with overdose of Ramoset. Expected effects of overdose would generally be an extension of known side effects, particularly severe constipation, headache, and potential QT-interval prolongation/arrhythmia.

In case of suspected overdose of Ramoset, seek immediate medical attention or contact emergency services/poison control. Treatment is supportive and symptomatic, including cardiac (ECG) monitoring where indicated; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use after the expiry date.

Elderly: Ramoset can generally be used in elderly patients; no major dose adjustment is typically required, but these patients may be more prone to constipation and QT-related effects, so monitor closely.

Renal impairment: Specific dose adjustment data for Ramoset in renal impairment are limited; use with caution and monitor for adverse effects.

Hepatic impairment: Use with caution as described under Precautions and Warnings.

Pediatric patients: See Pediatric Use.

Pregnancy and lactation: See Pregnancy and Lactation.

For prevention of chemotherapy-induced nausea and vomiting, Ramoset is given as a single dose before each chemotherapy cycle, per the treating oncologist's antiemetic protocol.

For IBS-D, Ramoset is typically used continuously on a once-daily basis, with clinical response and tolerability (especially constipation) reassessed periodically (e.g., after several weeks) by the prescribing physician, who will decide whether to continue, adjust the dose, or discontinue treatment.

Antiemetics; Gastrointestinal motility/serotonergic agents; Selective 5-HT3 (serotonin) receptor antagonists

Ramosetron Hydrochloride works by selectively and competitively blocking 5-HT3 receptors, which are ligand-gated ion channels activated by serotonin (5-hydroxytryptamine). By blocking these receptors on vagal afferent nerve terminals in the gut and in the chemoreceptor trigger zone of the brainstem, Ramosetron Hydrochloride suppresses the nausea/vomiting reflex triggered by chemotherapy. By blocking the same receptors on enteric neurons and sensory afferents in the colon, Ramosetron Hydrochloride slows colonic transit and reduces visceral hypersensitivity, which underlies its benefit in diarrhea-predominant IBS.

The safety and efficacy of Ramoset in pediatric patients have not been established. Ramoset is therefore not recommended for use in children and adolescents outside of specialist/investigational settings, and should only be considered in pediatric patients under the direct guidance of a specialist physician when no suitable alternative exists.